Promising results for CML
Tuesday, 09 December, 2008
Melbourne’s ChemGenex has released interim data of its Phase II/III trial of a compound for chronic myeloid leukaemia.
The trial involves 44 patients with the T315I mutation who have not responded to Novartis’ Glivec, or imatinib.
ChemGenex’s compound, omacetaxine mepesuccinate, showed good responses in chronic phase patients and was well tolerated, the company said.
The trial results were reported by trial investigator Jorge Cortes of the MD Anderson Cancer Center at a haematology conference in the US.
ChemGenex CEO Dr Greg Collier said the data would probably form part of the clinical section of the company’s new drug application to the US FDA next year.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
